Cannabinoid CB2 receptor and serotonin 5-HT1A receptor agonists have emerged as therapeutic options for their antidepressive and anxiolytic properties, apart from being linked to synergistic antinociceptive activity when used in combination in animal tests.
At the recent Macula Society Meeting, researchers from the Molecular Insight Research Foundation reported on the creation of a novel murine model of North Carolina macular dystrophy.
Immunesensor Therapeutics Inc. has presented preclinical data on the stimulator of interferon genes (STING) agonist IMSA-101 which is designed to modify the tumor microenvironment in solid tumors and thus improve the trafficking and infiltration of CAR T-cell therapy into the tumor.
In a recent study, scientists from Medical University of South Carolina aimed to evaluate whether immunogenic cell death (ICD) can trigger resistance to anticancer therapies and explore potential therapeutic opportunities to revive ICD and restore drug sensitivity.
Zapata Computing Inc. (Zapata AI) scientists have demonstrated the first instance of a generative model running on quantum hardware outperforming state-of-the-art classical models in generating viable cancer drug candidates.
Pulmonary arterial hypertension (PAH) is a severe condition characterized by vasoconstriction and remodeling of the small pulmonary arteries, driven by a complement-dependent activation of macrophages, for which an effective treatment is lacking. Chinese researchers have investigated the potential of a complement C3 inhibitor polypeptide, CP40-KK, as an approach for treating PAH. To do this, they used a model in which PAH was induced in rats by monocrotaline.
Autoantibodies call to mind disease – autoimmune disease, to be exact. But the physiological roles of autoantibodies are, at the very least, more complex than this view accounts for. “The autoantibody reactome is extraordinary,” Aaron Ring told BioWorld. “Nearly everyone has autoantibodies, whether they know it or not.”
Anadolu University and Atatürk University have jointly described novel 3,5-disubstituted-1,2,4-oxadiazole derived compounds acting as carbonic anhydrase type I and/or type II inhibitors.
RSS
